We recently demonstrated that these agonistic agents strongly reduced BxPc3 pancreatic-cancer cell migration [29], and suppressed tumor metastases in an orthotopic model of EphA2-driven aggressive prostate cancer [30]. This evidence concerns the gene EPHA2 and prostate cancer.